Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors. [PDF]
Fera T +10 more
europepmc +1 more source
3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors. [PDF]
Hays WB +6 more
europepmc +1 more source
Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial. [PDF]
Hamulyák EN +12 more
europepmc +1 more source
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair. [PDF]
Salazar CA +4 more
europepmc +1 more source
Factor Xa inhibitors vs. warfarin in patients with Hughes syndrome: a systematic review and meta-analysis of randomized controlled trials. [PDF]
Mohtashim A +13 more
europepmc +1 more source
The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis. [PDF]
Siegal DM +7 more
europepmc +1 more source
Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA-4: Time and Severity Matter Most. [PDF]
Concha M +10 more
europepmc +1 more source
Clinical and Economic Consequences of a First Major Bleeding Event in Patients Treated with Direct Factor Xa Inhibitors in Spain: A Long-Term Observational Study. [PDF]
Escobar C +9 more
europepmc +1 more source
Clinical Characteristics and Incidence of Hemorrhagic Complications in Patients Taking Factor Xa Inhibitors in Spain: A Long-Term Observational Study. [PDF]
Escobar C +8 more
europepmc +1 more source

